A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

P. Zisimopoulou, P. Evangelakou, J. Tzartos, K. Lazaridis, V. Zouvelou, R. Mantegazza, C. Antozzi, F. Andreetta, A. Evoli, F. Deymeer, G. Saruhan-Direskeneli, H. Durmus, T. Brenner, A. Vaknin, S. Berrih-Aknin, M. Frenkian Cuvelier, T. Stojkovic, M. DeBaets, M. Losen, P. Martinez-MartinezK. A. Kleopa, E. Zamba-Papanicolaou, T. Kyriakides, A. Kostera-Pruszczyk, P. Szczudlik, B. Szyluk, D. Lavrnic, I. Basta, S. Peric, C. Tallaksen, A. Maniaol, S. J. Tzartos

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Double-seronegative myasthenia gravis (dSN-MG, without detectable AChR and MuSK antibodies) presents a serious gap in MG diagnosis and understanding. Recently, autoantibodies against the low-density lipoprotein receptor-related protein 4 (LRP4) have been identified in several dSN-MG sera, but with dramatic frequency variation (~2-50%). We have developed a cell based assay (CBA) based on human LRP4 expressing HEK293 cells, for the reliable and efficient detection of LRP4 antibodies. We have screened about 800 MG patient sera from 10 countries for LRP4 antibodies. The overall frequency of LRP4-MG in the dSN-MG group (635 patients) was 18.7% but with variations among different populations (range 7-32.7%). Interestingly, we also identified double positive sera: 8/107 anti-AChR positive and 10/67 anti-MuSK positive sera also had detectable LRP4 antibodies, predominantly originating from only two of the participating groups. No LRP4 antibodies were identified in sera from 56 healthy controls tested, while 4/110 from patients with other neuroimmune diseases were positive. The clinical data, when available, for the LRP4-MG patients were then studied. At disease onset symptoms were mild (81% had MGFA grade I or II), with some identified thymic changes (32% hyperplasia, none with thymoma). On the other hand, double positive patients (AChR/LRP4-MG and MuSK/LRP4-MG) had more severe symptoms at onset compared with any single positive MG subgroup. Contrary to MuSK-MG, 27% of ocular dSN-MG patients were LRP4 antibody positive. Similarly, contrary to MuSK antibodies, which are predominantly of the IgG4 subtype, LRP4 antibodies were predominantly of the IgG1 and IgG2 subtypes. The prevalence was higher in women than in men (female/male ratio 2.5/1), with an average disease onset at ages 33.4 for females and 41.9 for males. Overall, the response of LRP4-MG patients to treatment was similar to published responses of AChR-MG rather than to MuSK-MG patients.

Original languageEnglish
Pages (from-to)139-145
Number of pages7
JournalJournal of Autoimmunity
Volume52
DOIs
Publication statusPublished - 2014

Fingerprint

Lipoprotein Receptors
Myasthenia Gravis
Epidemiology
Proteins
Antibodies
Serum
Immunoglobulin G
LDL-Receptor Related Proteins
Thymoma
LDL Receptors
HEK293 Cells
Age of Onset
Autoantibodies
Hyperplasia

Keywords

  • Autoantibodies
  • Cell based assay
  • Diagnosis
  • LRP4
  • Myasthenia gravis
  • Therapy

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. / Zisimopoulou, P.; Evangelakou, P.; Tzartos, J.; Lazaridis, K.; Zouvelou, V.; Mantegazza, R.; Antozzi, C.; Andreetta, F.; Evoli, A.; Deymeer, F.; Saruhan-Direskeneli, G.; Durmus, H.; Brenner, T.; Vaknin, A.; Berrih-Aknin, S.; Frenkian Cuvelier, M.; Stojkovic, T.; DeBaets, M.; Losen, M.; Martinez-Martinez, P.; Kleopa, K. A.; Zamba-Papanicolaou, E.; Kyriakides, T.; Kostera-Pruszczyk, A.; Szczudlik, P.; Szyluk, B.; Lavrnic, D.; Basta, I.; Peric, S.; Tallaksen, C.; Maniaol, A.; Tzartos, S. J.

In: Journal of Autoimmunity, Vol. 52, 2014, p. 139-145.

Research output: Contribution to journalArticle

Zisimopoulou, P, Evangelakou, P, Tzartos, J, Lazaridis, K, Zouvelou, V, Mantegazza, R, Antozzi, C, Andreetta, F, Evoli, A, Deymeer, F, Saruhan-Direskeneli, G, Durmus, H, Brenner, T, Vaknin, A, Berrih-Aknin, S, Frenkian Cuvelier, M, Stojkovic, T, DeBaets, M, Losen, M, Martinez-Martinez, P, Kleopa, KA, Zamba-Papanicolaou, E, Kyriakides, T, Kostera-Pruszczyk, A, Szczudlik, P, Szyluk, B, Lavrnic, D, Basta, I, Peric, S, Tallaksen, C, Maniaol, A & Tzartos, SJ 2014, 'A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis', Journal of Autoimmunity, vol. 52, pp. 139-145. https://doi.org/10.1016/j.jaut.2013.12.004
Zisimopoulou, P. ; Evangelakou, P. ; Tzartos, J. ; Lazaridis, K. ; Zouvelou, V. ; Mantegazza, R. ; Antozzi, C. ; Andreetta, F. ; Evoli, A. ; Deymeer, F. ; Saruhan-Direskeneli, G. ; Durmus, H. ; Brenner, T. ; Vaknin, A. ; Berrih-Aknin, S. ; Frenkian Cuvelier, M. ; Stojkovic, T. ; DeBaets, M. ; Losen, M. ; Martinez-Martinez, P. ; Kleopa, K. A. ; Zamba-Papanicolaou, E. ; Kyriakides, T. ; Kostera-Pruszczyk, A. ; Szczudlik, P. ; Szyluk, B. ; Lavrnic, D. ; Basta, I. ; Peric, S. ; Tallaksen, C. ; Maniaol, A. ; Tzartos, S. J. / A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. In: Journal of Autoimmunity. 2014 ; Vol. 52. pp. 139-145.
@article{63817489fb4b4fc28b1243d823b590b0,
title = "A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis",
abstract = "Double-seronegative myasthenia gravis (dSN-MG, without detectable AChR and MuSK antibodies) presents a serious gap in MG diagnosis and understanding. Recently, autoantibodies against the low-density lipoprotein receptor-related protein 4 (LRP4) have been identified in several dSN-MG sera, but with dramatic frequency variation (~2-50{\%}). We have developed a cell based assay (CBA) based on human LRP4 expressing HEK293 cells, for the reliable and efficient detection of LRP4 antibodies. We have screened about 800 MG patient sera from 10 countries for LRP4 antibodies. The overall frequency of LRP4-MG in the dSN-MG group (635 patients) was 18.7{\%} but with variations among different populations (range 7-32.7{\%}). Interestingly, we also identified double positive sera: 8/107 anti-AChR positive and 10/67 anti-MuSK positive sera also had detectable LRP4 antibodies, predominantly originating from only two of the participating groups. No LRP4 antibodies were identified in sera from 56 healthy controls tested, while 4/110 from patients with other neuroimmune diseases were positive. The clinical data, when available, for the LRP4-MG patients were then studied. At disease onset symptoms were mild (81{\%} had MGFA grade I or II), with some identified thymic changes (32{\%} hyperplasia, none with thymoma). On the other hand, double positive patients (AChR/LRP4-MG and MuSK/LRP4-MG) had more severe symptoms at onset compared with any single positive MG subgroup. Contrary to MuSK-MG, 27{\%} of ocular dSN-MG patients were LRP4 antibody positive. Similarly, contrary to MuSK antibodies, which are predominantly of the IgG4 subtype, LRP4 antibodies were predominantly of the IgG1 and IgG2 subtypes. The prevalence was higher in women than in men (female/male ratio 2.5/1), with an average disease onset at ages 33.4 for females and 41.9 for males. Overall, the response of LRP4-MG patients to treatment was similar to published responses of AChR-MG rather than to MuSK-MG patients.",
keywords = "Autoantibodies, Cell based assay, Diagnosis, LRP4, Myasthenia gravis, Therapy",
author = "P. Zisimopoulou and P. Evangelakou and J. Tzartos and K. Lazaridis and V. Zouvelou and R. Mantegazza and C. Antozzi and F. Andreetta and A. Evoli and F. Deymeer and G. Saruhan-Direskeneli and H. Durmus and T. Brenner and A. Vaknin and S. Berrih-Aknin and {Frenkian Cuvelier}, M. and T. Stojkovic and M. DeBaets and M. Losen and P. Martinez-Martinez and Kleopa, {K. A.} and E. Zamba-Papanicolaou and T. Kyriakides and A. Kostera-Pruszczyk and P. Szczudlik and B. Szyluk and D. Lavrnic and I. Basta and S. Peric and C. Tallaksen and A. Maniaol and Tzartos, {S. J.}",
year = "2014",
doi = "10.1016/j.jaut.2013.12.004",
language = "English",
volume = "52",
pages = "139--145",
journal = "Journal of Autoimmunity",
issn = "0896-8411",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis

AU - Zisimopoulou, P.

AU - Evangelakou, P.

AU - Tzartos, J.

AU - Lazaridis, K.

AU - Zouvelou, V.

AU - Mantegazza, R.

AU - Antozzi, C.

AU - Andreetta, F.

AU - Evoli, A.

AU - Deymeer, F.

AU - Saruhan-Direskeneli, G.

AU - Durmus, H.

AU - Brenner, T.

AU - Vaknin, A.

AU - Berrih-Aknin, S.

AU - Frenkian Cuvelier, M.

AU - Stojkovic, T.

AU - DeBaets, M.

AU - Losen, M.

AU - Martinez-Martinez, P.

AU - Kleopa, K. A.

AU - Zamba-Papanicolaou, E.

AU - Kyriakides, T.

AU - Kostera-Pruszczyk, A.

AU - Szczudlik, P.

AU - Szyluk, B.

AU - Lavrnic, D.

AU - Basta, I.

AU - Peric, S.

AU - Tallaksen, C.

AU - Maniaol, A.

AU - Tzartos, S. J.

PY - 2014

Y1 - 2014

N2 - Double-seronegative myasthenia gravis (dSN-MG, without detectable AChR and MuSK antibodies) presents a serious gap in MG diagnosis and understanding. Recently, autoantibodies against the low-density lipoprotein receptor-related protein 4 (LRP4) have been identified in several dSN-MG sera, but with dramatic frequency variation (~2-50%). We have developed a cell based assay (CBA) based on human LRP4 expressing HEK293 cells, for the reliable and efficient detection of LRP4 antibodies. We have screened about 800 MG patient sera from 10 countries for LRP4 antibodies. The overall frequency of LRP4-MG in the dSN-MG group (635 patients) was 18.7% but with variations among different populations (range 7-32.7%). Interestingly, we also identified double positive sera: 8/107 anti-AChR positive and 10/67 anti-MuSK positive sera also had detectable LRP4 antibodies, predominantly originating from only two of the participating groups. No LRP4 antibodies were identified in sera from 56 healthy controls tested, while 4/110 from patients with other neuroimmune diseases were positive. The clinical data, when available, for the LRP4-MG patients were then studied. At disease onset symptoms were mild (81% had MGFA grade I or II), with some identified thymic changes (32% hyperplasia, none with thymoma). On the other hand, double positive patients (AChR/LRP4-MG and MuSK/LRP4-MG) had more severe symptoms at onset compared with any single positive MG subgroup. Contrary to MuSK-MG, 27% of ocular dSN-MG patients were LRP4 antibody positive. Similarly, contrary to MuSK antibodies, which are predominantly of the IgG4 subtype, LRP4 antibodies were predominantly of the IgG1 and IgG2 subtypes. The prevalence was higher in women than in men (female/male ratio 2.5/1), with an average disease onset at ages 33.4 for females and 41.9 for males. Overall, the response of LRP4-MG patients to treatment was similar to published responses of AChR-MG rather than to MuSK-MG patients.

AB - Double-seronegative myasthenia gravis (dSN-MG, without detectable AChR and MuSK antibodies) presents a serious gap in MG diagnosis and understanding. Recently, autoantibodies against the low-density lipoprotein receptor-related protein 4 (LRP4) have been identified in several dSN-MG sera, but with dramatic frequency variation (~2-50%). We have developed a cell based assay (CBA) based on human LRP4 expressing HEK293 cells, for the reliable and efficient detection of LRP4 antibodies. We have screened about 800 MG patient sera from 10 countries for LRP4 antibodies. The overall frequency of LRP4-MG in the dSN-MG group (635 patients) was 18.7% but with variations among different populations (range 7-32.7%). Interestingly, we also identified double positive sera: 8/107 anti-AChR positive and 10/67 anti-MuSK positive sera also had detectable LRP4 antibodies, predominantly originating from only two of the participating groups. No LRP4 antibodies were identified in sera from 56 healthy controls tested, while 4/110 from patients with other neuroimmune diseases were positive. The clinical data, when available, for the LRP4-MG patients were then studied. At disease onset symptoms were mild (81% had MGFA grade I or II), with some identified thymic changes (32% hyperplasia, none with thymoma). On the other hand, double positive patients (AChR/LRP4-MG and MuSK/LRP4-MG) had more severe symptoms at onset compared with any single positive MG subgroup. Contrary to MuSK-MG, 27% of ocular dSN-MG patients were LRP4 antibody positive. Similarly, contrary to MuSK antibodies, which are predominantly of the IgG4 subtype, LRP4 antibodies were predominantly of the IgG1 and IgG2 subtypes. The prevalence was higher in women than in men (female/male ratio 2.5/1), with an average disease onset at ages 33.4 for females and 41.9 for males. Overall, the response of LRP4-MG patients to treatment was similar to published responses of AChR-MG rather than to MuSK-MG patients.

KW - Autoantibodies

KW - Cell based assay

KW - Diagnosis

KW - LRP4

KW - Myasthenia gravis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84904307500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904307500&partnerID=8YFLogxK

U2 - 10.1016/j.jaut.2013.12.004

DO - 10.1016/j.jaut.2013.12.004

M3 - Article

C2 - 24373505

AN - SCOPUS:84904307500

VL - 52

SP - 139

EP - 145

JO - Journal of Autoimmunity

JF - Journal of Autoimmunity

SN - 0896-8411

ER -